Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

Summary

To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.

Timeline

Start

2003-01-08

Primary completion

2004-12-08

Completion

2004-12-08

Publications

• Background van Adelsberg J, Gann P, Ko AT, Damber JE, Logothetis C, Marberger M, Schmitz-Drager BJ, Tubaro A, Harms CJ, Roehrborn C. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin. 2007 Sep;23(9):2063-70. doi: 10.1185/030079907X219526.

Drugs

Indications